Arena/Eisai anti-obesity drug wins US FDA nod; CVOT postapproval, no REMS
This article was originally published in Scrip
Executive Summary
Obese and overweight patients will have a new drug to combat those conditions with the US FDA giving its final blessing on 27 June to Arena Pharmaceuticals’ and Eisai's lorcaserin, which will be sold in the US under the brand name Belviq as an adjunct to a reduced-calorie diet and exercise for chronic weight management.
You may also be interested in...
FDA Requests Belviq Be Pulled From The US Market Due To Cancer Risk
The agency requested the weight loss pill be voluntarily recalled by Eisai, the death knell for a trio of obesity drugs that launched early in the last decade.
FDA Requests Belviq Be Pulled From The US Market Due To Cancer Risk
The agency requested the weight loss pill be voluntarily recalled by Eisai, the death knell for a trio of obesity drugs that launched early in the last decade.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.